Potential Repurposing of Drugs with Anti-SARS-CoV-2 Activity in Preclinical Trials: A Systematic Review

Author(s): Yasmim Mendes Rocha, Gabriel Acácio de Moura, Juliana Ramos de Oliveira, Larissa Deadame de Figueiredo Nicolete, Roberto Nicolete*

Journal Name: Current Medicinal Chemistry

Volume 28 , Issue 22 , 2021

Become EABM
Become Reviewer
Call for Editor


COVID-19 is an emerging outbreak similar to previous pandemics caused by Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Till date, SARS-CoV-2 infection is still spreading, representing a major threat to public health, where several control measures are being practiced in order to culminate its spread. The research and development of new drugs require a lot of funding in addition to being a slow and costly process. As a result, new techniques have been proposed to streamline this process. The repositioning or repurposing of drugs represents an attractive strategy, presenting a promising way to introduce new drugs. Currently, numerous reused drugs are already available in the market and are in practice. In this review, it was observed that the antiviral drugs Entricitabine and Tenofovir display potential therapeutic efficacy in preclinical studies. Therefore, in silico analyses were considered a potential tool for predicting the effectiveness of drugs, mainly as an effective approach to encourage a complementary in vitro and in vivo antiviral evaluation.

Keywords: Covid-19, SARS-CoV-2, drugs, repurposing, antivirals, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 02 August, 2021
Page: [4577 - 4585]
Pages: 9
DOI: 10.2174/0929867327666201005113204
Price: $65

Article Metrics

PDF: 228